ANIX - OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
German Life Science IT company OntoChem GmbH has assigned its drug discovery technologies and assets, including its drug discovery collaboration with Anixa Biosciences (ANIX), to newly formed MolGenie GmbH.Anixa and OntoChem were seeking to develop an orally administrable, metabolically stable, non-toxic anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19.The company is now working with MolGenie to use the generated compounds and data to advance the project to its next stage of development.
For further details see:
OntoChem assigns Anixa covid-19 drug discovery project to MolGenie